Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
April 24, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation
April 23, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer
April 19, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Participate in the Leerink Partners’ 2018 CNS Day
April 11, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
March 27, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference
March 26, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at 17th Annual Needham Healthcare Conference
March 19, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
March 12, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
March 07, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018
February 28, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...